Sanofi

News Hour: Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States. Under the terms of the agreement, Sanofi will make an upfront payment...

News Hour: Sanofi announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Insulin lispro Sanofi® (insulin lispro 100...

News Hour: Sanofi announced the appointment of Bill Sibold as Executive Vice President Sanofi Genzyme, effective July 1, 2017.  In this role, Mr. Sibold will be a member of the Executive Committee. He succeeds David Meeker,...

News Hour: Sanofi and its vaccines global business unit Sanofi Pasteur announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to develop and commercialize a monoclonal antibody–called MEDI8897–for the prevention of...

News Hour: At its meeting held on March 2, 2017, the Board of Directors of Sanofi proposed the appointment of Melanie Lee, PhD and Bernard Charlès as new independent Directors during the General Shareholders’ meeting of...

News Hour: Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies. Specifically, two formulations of...

News Hour: Sanofi and Regeneron Pharmaceuticals, Inc. today announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an...

News Hour: Sanofi announced the appointment of Kathleen Tregoning as a new member of the Executive Committee, effective February 27, 2017. Ms. Tregoning joins Sanofi from Biogen where she served as Senior Vice President of Corporate Affairs....

News Hour: Sanofi announced that the European Commission has granted marketing authorization in Europe for SuliquaTM, the once-daily titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of...

News Hour: Sanofi and Regeneron Pharmaceuticals, Inc. announced that they will appeal the injunction granted today by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent® in the...